The antipsychotic drug prochlorperazine was screened in vitro for possible antimicrobial property against 157 strains of bacteria, belonging to Gram positive and Gram negative genera. The minimum inhibitory concentration (MIC) of prochlorperazine was determined by agar dilution method, which ranged from 25 to 200 mg/ml with respect to most of the strains. Based on such findings, a further study was undertaken to determine whether the efficacy of this drug could be enhanced in the presence of an antihistaminic agent methdilazine, reported to have remarkable antimicrobial action. Four bacterial strains, sensitive to prochlorperazine as well as to three antibacterial chemotherapeutics, viz., methdilazine, fluphenazine and thioridazine were chosen. Disc diffusion tests with prochlorperazine and methdilazine revealed marked synergism between the combination, compared to their individual effects. The synergism was found to be statistically significant (po0.01). To assess the degree of synergism, the checkerboard analysis was performed. The FIC index of this combination turned out to be 0.37, which confirmed synergism. Therefore, this synergistic drug combination might open a new therapeutic approach to combat drugresistance in bacterial infections.
Introduction
Antibiotics and antibacterial chemotherapeutics exist in large numbers in today's pharmaceutical market. Despite that, their use is becoming increasingly restricted. The reason behind such a rapid decline is largely attributed to the development of drug resistance among microorganisms. Such a phenomenon is coupled by the toxicity possessed by many antimicrobials. There is, thus, a search for newer antimicrobial agents that can overcome these drawbacks. Studies in this line have exposed the fact that several compounds, belonging to various pharmacological classes, possess moderate to powerful antibacterial activity. Such compounds, having antimicrobial properties in addition to their predesignated pharmacological actions, have been called the 'Non-antibiotics' (Kristiansen, 1992) . Examples include the antihistamines like bromodiphenhydramine and diphenhydramine (Dastidar et al., 1976) , methdilazine (Chattopadhyay et al., 1988) , promethazine (Chakrabarty et al., 1989) and fluphenazine (Dastidar et al., 1995) , antipsychotic agents like chlorpromazine (Molnár et al., 1976) , promazine (Dash et al., 1977) , thioridazine (Radhakrishnan et al., 1999) , trifluoperazine (Mazumder et al., 2001 ) and triflupromazine (Dastidar et al., 2004) , antihypertensives like propranolol (Manna and Dastidar, 1984) and methyl-DOPA (Dastidar et al., 1986) and antiinflammatory agents like diclofenac (Annadurai et al., 1998) . Based on such findings, the present study was undertaken to determine antibacterial action in yet another antipsychotic agent prochlorperazine. Further, most of the previously reported non-antibiotics have shown that their action could be augmented by making suitable combinations with other drugs. Hence, in the present study, prochlorperazine (Pcp) was used in combination with an antihistaminic non-antibiotic methdilazine (Md) to test for synergism between the two drugs.
Materials and methods
Bacteria. One hundred and fifty-seven strains, belonging to three Gram positive and 13 Gram negative genera were tested. They were human isolates, identified by the method of (Collee et al., 1996) . They were preserved in freeze-dried state and at 4 1C in stab slant agar.
Drugs. All the drugs were obtained from their respective manufacturers in India in pure dry powder form. They were preserved at 4 1C.
Media. The liquid media used were nutrient broth (NB; Oxoid), peptone water (PW; Oxoid bacteriological peptone 1% plus Analar NaCl 0.5%) and Mueller-Hinton broth (MHB; Oxoid). The solid media were nutrient agar (NA), peptone agar (PA) and Mueller-Hinton agar (MHA), obtained by solidifying the above liquid media with 1.0% agar (Oxoid, No. 3) . NA was used for growing Gram positive bacteria, while PA and MHA were used for the rest of the bacteria as needed.
Determination of MIC of prochlorperazine. Gram positive bacteria were grown in NB and Gram negative ones in PW for 18 h and harvested during the stationary growth phase. A direct suspension of organisms was prepared in 5 ml sterile distilled water. The turbidity of the suspension was adjusted to match a 0.5 McFarland standard (McFarland, 1907) with a spectrophotometer (Chemito UV 2600 Double Beam UV-Vis Spectrophotometer) at 625 nm, which corresponded to 2.4 Â 10 8 colony forming units (cfu)/ml. The inocula were prepared by further diluting the suspension 1:100 with sterile distilled water such that a 2 mm (internal diameter) loopful of a culture contained 10 5 cfu. These were spot-inoculated on the NA plates containing increasing amounts of the drug, including a control. The plates were incubated at 37 1C, examined for appearance of growth after 24 h and extended up to 72 h where necessary. Pcp was dissolved in sterile distilled water and individually added to the molten NA at concentrations of 0 (control), 10, 25, 50, 100, 200, 400 and 800 mg/ml, and subsequently poured into sterile Petridishes under aseptic conditions, maintaining the pH at 7.2-7.4.
In vitro synergism. Determination of the combined effects of Pcp and Md by disc diffusion technique was based on the method described by National Committee for Clinical Laboratory Standards (NCCLS) (2001). Sterile filter paper discs (7.25 mm, Whatman No. 1) containing 200 mg of each drug were prepared according to Cruickshank et al. (1975) . The sensitive bacteria were grown in liquid media for 18 h and flooded on appropriate solid media in triplicate. The plates were then dried at 37 1C for 45 min. The drugsoaked filter paper discs were placed on the lawns and incubated at 37 1C for 18 h. The subsequent zones of inhibition around each disc were measured in three different directions and mean diameters were recorded. Individual inhibitory effects of Pcp and Md were determined first. For determination of combined effects of these two drugs, the drug-discs were placed on flooded agar plates in such a manner that the inhibitory circles would just touch each other tangentially. In this way, the diameters of inhibition zones produced due to individual and mutual effects on the same plate were recorded.
The increase in surface area (pr 2 ), if any, due to a combination of effects was statistically evaluated by the Student's 't' test for its level of significance. The occurrence of mutual influence/interference when the drugs were used in combination was assessed as follows: (i) indifference, when both the tangential circles of inhibition remained unaffected; (ii) antagonism, when the circles of inhibition receded and assumed kidney shape; (iii) synergism, in which there was enlargement of circles.
Checkerboard procedure. Synergy testing was performed for four strains by the checkerboard method in microtiter trays with MHB (Eliopoulos and Moellering, 1996) . Both Md and Pcp were tested at concentrations of 6.25-200 mg/ml. The trays were prepared with a 96-channel dispenser and stored at À70 1C until use. Md was dispensed alone in the first row, and Pcp was dispensed in the first column. An inoculum of 0.5 McFarland standard was applied using multipoint inoculator. The trays were incubated aerobically overnight (standard quality control strains were included in each run).
End-point determination. The MIC was read as the lowest concentration of antimicrobial agents showing no visible growth or only a faint haze. MICs were determined for each agent individually and in combination.
Data analysis. Synergy was determined by calculating the fractional inhibitory concentration (FIC) index as follows:
where [A] is the concentration of drug A for the organism, FIC A is the FIC of drug A, MIC A is the MIC of drug A, and [B] , MIC B , and FIC B are defined in the same fashion for drug B. Results for synergy testing were defined according to guidelines established by the American Society for Microbiology, Instruction to Authors (1995) , so that a given FIC index was interpreted as follows: o0.5, synergy; 0.5-0.75, partial synergy; 0.76-1.0, additive effect; 41.0-4.0, indifference; and 44.0, antagonism. Chi-square analysis was performed to determine differing rates of synergy between the drugs.
Results

Antibacterial activity of prochlorperazine by in vitro screening
Out of eight strains of Bacillus spp., one was inhibited by Pcp at 100 mg/ml and the rest seven at 200 mg/ml. Among 28 strains of staphylococci tested, 19 were inhibited within 50 mg/ml, eight strains at 100 mg/ml and the remaining one strain at 200 mg/ml. Strains of E. coli, Salmonella, Klebsiella and Pseudomonas were either moderately sensitive (MIC 50-400 mg/ml) or resistant (MIC 800 or 4800 mg/ml) to the drug. Out of 17 strains of Shigella spp., seven stopped growing at 25 mg/ml, two at 50 mg/ml, five strains at 400 mg/ml and the remaining three strains at 800 mg/ml. For the vibrios the MIC of Pcp ranged from 25 to 200 mg/ ml for most of the strains. Certain enterobacteria like Proteus, Providencia, Citrobacter, Bordetella and Arizona were less sensitive to Pcp (MIC 400-800 mg/ml) while Hafnia and Pasteurella were more sensitive (Table 1) .
MIC of prochlorperazine and some other phenothiazines towards Gram positive and Gram negative bacteria
The MIC of Md, fluphenazine (Fz), thioridazine (Tz) and Pcp were tested with respect to Bacillus pumilus NCTC 8241, Staphylococcus aureus NCTC 8530, Shigella dysenteriae 7 NCTC 519/66 and Vibrio cholerae ATCC 14035. The MIC of Md, Fz and Tz ranged from 10 to 50 mg/ml with respect to all the strains tested, whereas, the MIC of Pcp was 25 mg/ml against Shigella dysenteriae 7 NCTC 519/ 66, 100 mg/ml with respect to Vibrio cholerae ATCC 14035 and 200 mg/ml against the two Gram positive bacteria (B. pumilus NCTC 8241 and Staphylococcus aureus NCTC 8530; Table 2 ).
Evidence of in vitro synergism
It was noticed that there was marked increase in surface areas of zones of inhibition produced due to combination of Pcp individually with all three agents Md, Fz and Tz, compared to their individual effects. However, the combination of Pcp and Md proved to be most synergistic compared to the other two combinations (Table 3 ; Fig. 1 ). The percentages of increase in surface area of zones of inhibition for this combination ranged from 18.50 in case of Staphyloccus aureus to 44.26 in case of Sh. dysenteriae 7 NCTC 519/66 (Table 3 ). The synergism between Pcp and Md was further scrutinized by the Checkerboard experiment using doubling dilutions ranging from 0 to 200 mg/ml for both the drugs. The MIC of Pcp and Md for Shigella dysenteriae 7 NCTC 519/66 were 25 mg/ml, while in combination the values were 6.25 and 12.5, respectively. The FIC index for Shigella dysenteriae 7 NCTC 519/66 was found to be 0.37, which again confirmed synergism.
Discussion
The antipsychotic agent prochlorperazine was seen to possess powerful antimicrobial activity in vitro. While sensitive bacterial strains occurred among Bacillus spp., Staphylococcus aureus, Vibrio spp. and some enterobacteria, the drug was less powerful with respect to strains of E. coli, Salmonella spp., shigellae, Klebsiella spp. and Pseudomonas spp. (Table 1) .
The most important device employed by clinicians in selecting appropriate antimicrobial therapy for a particular infection has been the susceptibility profile or MIC of the agent. Use of two agents to treat a pathogenic infection is a standard practice, and the clinician's choice of these agents is again directed by their susceptibility profile for the pathogens. However, with the amplified frequency of multidrug resistant organisms, often only one (or one class of) agent remains to which the pathogen is susceptible (on the basis of the MIC) and monotherapy may be preferred, which might result in treatment failure or suboptimal treatment of the infection. Selecting only those antibiotics to which the organism is interpreted as being susceptible and not those to which it is considered to be resistant by the MIC implies that the advantage of combination therapy (preferably synergism) is obtained only when the organism is susceptible to both agents. Earlier studies by different workers have revealed commendable synergistic action between two drugs. The antibacterial activities of both the antiinflammatory non-antibiotic drug diclofenac as well as the aminoglycoside antibiotic streptomycin were enhanced, when used in combination, proving synergism between them (Annadurai et al., 2002) . Furthermore, diclofenac showed increased antibacterial efficacy when paired with another nonantibiotic trifluoperazine (Dastidar et al., 2003) .
ARTICLE IN PRESS
In the present study, augmentation of antimicrobial activity of the non-antibiotic prochlorperazine in combination with another non-antibiotic methdilazine has been shown. Quantitative estimation using percent increase in surface area of the individual inhibition zones compared with those produced by the combination showed a noteworthy enhancement of activity (Table 3 ). This in vitro activity was statistically significant. The checkerboard titration also yielded significant synergy (Fig. 2) . Pcp, prochlorperazine, Md, methdilazine. Mean surface area of the inhibition zone (mm 2 ) was calculated as pr 2 on the basis of the mean diameter (2r) and % increase was calculated as (B-A)/A Â 100, which was highly significant (po0.01). The zones of inhibition formed combinedly with respect to Pcp and Md were larger in size than those formed singly against the same compounds. These were calculated statistically by determining Student's 't' test based on the values of standard deviation and standard error obtained, which showed the differences to be highly significant (po0.01) with respect to all the test bacteria. Since both the drugs have been used acceptably for a long time for other therapeutic purposes, their fairly low toxicity and safety margins observed during human application are encouraging.
Evidence of antibacterial activity possessed by prochlorperazine and the synergistic rejoinder of such activity in combination with methdilazine shows that this non-antibiotic independently and in suitable combinations manifests a broad spectrum of activity against Gram positive and Gram negative bacteria. It may be concluded therefore that such a synergistic combination of drugs, having the potentiality to act against a larger variety of bacteria, is expected to support us in fighting drugresistance and further serve as a powerful device in the selection of an appropriate antimicrobial therapy.
